ARTHRITIS CARE & RESEARCH 是美国风湿病学会和风湿病健康专业人员协会（学院的一个部门）的官方期刊，是一份同行评议的出版物，发表原创研究、评论文章和社论，以促进在风湿病临床实践。与风湿病患者的护理相关，主要主题是循证实践研究、临床问题、实践指南、教育、社会和公共卫生问题、卫生经济学、卫生保健政策以及风湿病实践的未来趋势。

Arthritis Care and Research is the official journal of the American College of Rheumatology and the Association of Rheumatology Health Professionals (a division of the college). This peer-reviewed publication features original research, review articles, and editorials aimed at advancing clinical practice in rheumatology. The journal primarily addresses topics related to the care of patients with rheumatic diseases, including evidence-based practice research, clinical issues, practice guidelines, education, social and public health issues, health economics, healthcare policy, and future trends in rheumatology practice.

《Arthritis Care and Research》是美国风湿病学会和风湿病健康专业人员协会（学院的一个部门）的官方期刊。这是一份经过同行评审的学术期刊，发表原创研究、评论文章和社论，旨在促进风湿病的临床实践。期刊主要关注与风湿病患者护理相关的主题，包括循证实践研究、临床问题、实践指南、教育、社会和公共卫生问题、卫生经济学、卫生保健政策以及风湿病实践的未来趋势。

Arthritis Care and Research

To propose a common nomenclature to refer to individuals who fulfill the American College of Rheumatology classification criteria for systemic lupus erythematosus (SLE) during childhood or adolescence.The medical literature was reviewed for studies conducted in the target population between 1960 and December 2011 to obtain information about the terms used to refer to such children and adolescents. We reviewed the threshold ages used and disease features considered to discriminate these individuals from patients with onset of SLE during adulthood. Furthermore, the nomenclature used in other chronic diseases with onset during both childhood and adulthood was assessed.There was an astonishing variability in the age cutoffs used to define SLE onset prior to adulthood, ranging from 14-21 years, but most studies used age 18 years. The principal synonyms in the medical literature were SLE without reference to the age at onset of disease, childhood-onset SLE, juvenile SLE, and pediatric (or paediatric) SLE.Based on the definition of childhood, in analogy with other complex chronic diseases commencing prior to adulthood, and given the current absence of definite genetic variations that discriminate adults from children, the term childhood-onset SLE is proposed when referring to individuals with onset of SLE prior to age 18 years.

Clovis A. Silva

Tadej Avcin

Hermine I. Brunner

Arthritis Care & Research

Arthritis Care Res

Taxonomy for systemic lupus erythematosus with onset before adulthood

儿童起病的系统性红斑狼疮分类

Gillian A Hawker

Samra Mian

Tetyana Kendzerska

Melissa French

Arthritis care & research

Arthritis Care Res (Hoboken)

Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP).

成人疼痛评估量表：视觉模拟疼痛量表（VAS Pain）、数字疼痛评分量表（NRS Pain）、麦吉尔疼痛问卷（MPQ）、简明麦吉尔疼痛问卷（SF-MPQ）、慢性疼痛分级量表（CPGS）、简明健康调查问卷身体疼痛量表（SF-36 BPS）及间歇性和持续性骨关节炎疼痛量表（ICOAP）。

Objective Little is known of the clinical features and comorbidity profile of patients presenting with early‐onset gout (EOG), although international guidelines recommend rapid treatment after diagnosis. The objective of this study was to assess specific characteristics and comorbidities of patients with gout who had an early onset. Methods Patients from a cross‐sectional French national cohort who experienced their first gout flare before age 40 years were included in the EOG group and compared to patients with an onset after age 40 years, the common gout group. Results A total of 120 patients were included in the EOG group (mean ± SD age 49.5 ± 11.9 years) and 865 patients in the common gout group (mean ± SD age 64.4 ± 10.1 years). Patients with EOG more often presented with a history of polyarticular flares ( P &lt; 0.01), but had similar frequency of flares ( P = 0.16), gout arthropathy ( P = 0.79), and tophi ( P = 0.53). Prevalence of each item comprising metabolic syndrome did not differ between groups. In patients with EOG, all cardiovascular comorbidities were diagnosed after gout onset. Greater age, low high‐density lipoprotein, and excessive alcohol intake were associated in multivariate analysis with the common gout group, while a familial history of gout, longer duration of urate‐lowering treatment, higher serum uric acid levels, and metabolic syndrome were associated with the EOG group. Conclusion Patients with EOG developed slightly more severe joint involvement and earlier metabolic disorders than patients with common gout.

Tristan Pascart

Laurène Norberciak

Hang‐Korng Ea

Pascal Guggenbuhl

Frédéric Lioté

Patients With Early‐Onset Gout and Development of Earlier Severe Joint Involvement and Metabolic Comorbid Conditions: Results From a Cross‐Sectional Epidemiologic Survey

早发性痛风患者早期严重关节受累及代谢共病的发展：一项横断面流行病学调查的结果

Abstract Objective To determine the prevalence, interrelation, and impact of musculoskeletal disorders of the upper limb in the general population. Methods A total of 9,696 randomly selected adults of working age were surveyed in a 2‐stage cross‐sectional study involving a screening questionnaire and a standardized physical examination in symptomatic subjects. Age‐ and sex‐specific prevalence rates were estimated for several musculoskeletal disorders and for nonspecific pain in the upper limbs. The overlap and impact on daily activities and healthcare utilization were explored. Results Among 6,038 first‐stage responders, 3,152 reported upper limb symptoms and 1,960 were subsequently examined. Of subjects with pain, 44.8% had 1 or more specific soft‐tissue disorders. Site‐specific prevalence rates were as follows: shoulder tendinitis 4.5% among men and 6.1% among women; adhesive capsulitis 8.2% among men and 10.1% among women; lateral epicondylitis 1.3% among men and 1.1% among women; de Quervain's disease 0.5% among men and 1.3% among women; other tenosynovitis of the hand or wrist, 1.1% among men and 2.2% among women. Specific disorders tended to cluster ( P &lt; 0.001) in individuals, with particular overlap at the shoulder. Compared with subjects with nonspecific pain, those with specific disorders more often reported inability to perform everyday tasks ( P &lt; 0.05), consultation with a doctor ( P &lt; 0.05), and use of prescribed medication ( P &lt; 0.05). Conclusion Upper limb pain is common in the general population and is often associated with physical signs suggestive of specific upper‐limb disorders. These disorders have a substantial impact on physical function and use of health care.

Karen Walker‐Bone

Keith T. Palmer

Isabel Reading

David Coggon

Cyrus Cooper

Arthritis &amp; Rheumatism

Prevalence and impact of musculoskeletal disorders of the upper limb in the general population

一般人群上肢肌肉骨骼疾病的患病率及影响

Objective To investigate the efficacy and safety of creatine supplementation in fibromyalgia patients. Methods A 16‐week, randomized, double‐blind, placebo‐controlled, parallel‐group trial was conducted. Fibromyalgia patients were randomly assigned to receive either creatine monohydrate or placebo in a double‐blind manner. The patients were evaluated at baseline and after 16 weeks. Muscle function, aerobic conditioning, cognitive function, quality of sleep, quality of life, kidney function, and adverse events were assessed. Muscle phosphorylcreatine content was measured through 31 P magnetic resonance spectroscopy. Results After the intervention, the creatine group presented higher muscle phosphorylcreatine content when compared with the placebo group (+80.3% versus −2.7%; P = 0.04). Furthermore, the creatine group presented greater muscle strength than the placebo group in the leg press and chest press exercises (+9.8% and +1.2% for creatine versus −0.5% and −7.2% for placebo, respectively; P = 0.02 and P = 0.002, respectively). Isometric strength was greater in the creatine group than in the placebo group (+6.4% versus −3.2%; P = 0.007). However, no general changes were observed in aerobic conditioning, pain, cognitive function, quality of sleep, and quality of life. Food intake remained unaltered and no side effects were reported. Conclusion Creatine supplementation increased intramuscular phosphorylcreatine content and improved lower‐ and upper‐body muscle function, with minor changes in other fibromyalgia features. These findings introduce creatine supplementation as a useful dietary intervention to improve muscle function in fibromyalgia patients.

Christiano R. R. Alves

Bianca M. Santiago

Fernanda R. Lima

Maria C. G. Otaduy

Ana Luisa Calich

Aline C. C. Tritto

Ana Lúcia de Sá Pinto

Hamilton Roschel

Cláudia C. Leite

Fabiana B. Benatti

Eloisa Bonfá

Bruno Gualano

Creatine Supplementation in Fibromyalgia: A Randomized, Double‐Blind, Placebo‐Controlled Trial

肌酸补充剂在纤维肌痛中的应用：一项随机、双盲、安慰剂对照试验

Habitual movement compensations, such as decreased surgical peak knee extension moments (pKEM), persist years after total knee arthroplasty (TKA), are linked to poorer recovery, and may influence contralateral osteoarthritis (OA) progression. The purpose of this randomized clinical trial was to determine if a movement training program (MOVE) improves movement quality and recovery after TKA compared to a standardized rehabilitation program without movement training (CONTROL).

Michael J. Bade

Cory L Christiansen

Joseph A. Zeni

Michael R Dayton

Jeri E. Forster

Victor Cheuy

Jesse C. Christensen

Craig Hogan

Ryan Koonce

Doug Dennis

Amy Peters

Jennifer E. Stevens‐Lapsley

Movement pattern biofeedback training after total knee arthroplasty: a randomized controlled trial

全膝关节置换术后运动模式生物反馈训练：一项随机对照试验

Objective This studied investigated whether changes in circulating biomarkers predict progressive pulmonary fibrosis (PFF) in patients with systemic sclerosis‐associated interstitial lung disease (ILD) receiving treatment. Method Participants of Scleroderma Lung Study (SLS) II, which compared mycophenolate (MMF) versus cyclophosphamide (CYC) for SSc‐ILD, who had blood samples at baseline and 12‐months were included. Levels for C‐reactive protein (CRP), interleukin (IL)‐6, chemokine ligand 4 (CXCL4), chemokine ligand 18 (CCL18) and Krebs von den Lungen 6 (KL‐6) were measured, and a logistic regression model evaluated relationships between changes in these biomarkers and the development of PPF by 24 months. Results Ninety‐two of the 142 randomized participants had longitudinal biomarker measurements and the required clinical outcome data, with 19 (21%) meeting criteria for PPF. In the whole cohort, changes in KL‐6 levels were significantly correlated with PPF. KL‐6 increased in patients who developed PPF and decreased in patients who did not (Mean change 365.68 [SD 434.41]) vs ‐207.45 [SD 670.26]; P&lt;0.001). In the MMF alone arm, changes in CRP and CXCL4 were also significantly correlated with PPF. When added to an existing prediction model based on baseline factors associated with PPF in this cohort (sex, baseline reflux severity and CXCL4 levels), the change in KL‐6 remained significantly associated with PFF (OR 1.4; P=0.0002). Conclusion Changes in the circulating levels of KL‐6 after treatment with MMF or CYC predicted PPF, even after adjusting for baseline factors associated with PPF. Measuring longitudinal KL‐6 in patients with SSc‐ILD may improve how we personalize therapy in SSc‐ILD.

Elizabeth R. Volkmann

Holly Wilhalme

Donald P. Tashkin

Grace Hyun J. Kim

Jonathan Goldin

Alana Haussmann

Masataka Kuwana

Michael D. Roth

Shervin Assassi

Treatment Response Biomarkers for Systemic Sclerosis‐Associated Interstitial Lung Disease

系统性硬化症相关间质性肺疾病的治疗反应生物标志物

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Ana L. Altaffer

Lindsay C. Burrage

Ankur Kamdar

Tiphanie P. Vogel

Maria Pereira

The Matter at Hand: A Case of Difficult‐to‐Treat Arthritis

手头的问题：一例难治性关节炎病例

Objective The aim of this research was to determine how common gout flares are after ceasing anti‐inflammatory prophylaxis. Methods A rapid literature review and meta‐analysis were undertaken. PubMed was searched from inception to February 2024. Eligibility criteria included: any clinical trial of people with gout with at least one arm starting or intensifying ULT with co‐prescription of anti‐inflammatory prophylaxis, and the percentage of participants experiencing ≥ one gout flare reported during and after the period of prophylaxis. Random effects meta‐analyses were used to generate pooled estimates of the percentage of participants experiencing ≥ one flare in each period. Findings Six trials included, together with aggregated, unpublished data from the VA‐STOP Gout trial (2972 participants). Pooled random effects estimates (95% CI) of the percentage of participants having ≥ one gout flare were 14.7% (11.3%‐18.5%) during prophylaxis, 29.7% (22.9%‐37.0%) in the three‐month period after ceasing prophylaxis and 12.2% (6.8%‐19.0%) during the last study period. The mean difference in the percentage of participants having ≥ one gout flare while on prophylaxis and immediately after ceasing prophylaxis was ‐14.8.0% (‐21.2% to ‐8.5%)(p&lt;0.0001). The mean difference from the period immediately following prophylaxis discontinuation compared to the last study period was 16.0% (p&lt;0.001). Sensitivity analyses indicated no material effects of prophylaxis duration, trial duration, ULT class, or placebo arms. Interpretation Gout flares are common after stopping anti‐inflammatory prophylaxis but return to levels seen during prophylaxis. Patients should be cautioned about the risk of gout flares and have a plan for effective gout flare management in the three months after stopping anti‐inflammatory prophylaxis.

Lisa K Stamp

Christopher Frampton

Jeff A. Newcomb

James R. O'Dell

Ted R. Mikuls

Nicola Dalbeth

Gout flares after stopping anti‐inflammatory prophylaxis: a rapid literature review and meta‐analysis

停用抗炎预防后痛风发作的快速文献综述与荟萃分析

Jui‐Man Chang

Lien‐Chung Wei

Response to "Incidence of and Risk of Mortality After Hip Fractures in Rheumatoid Arthritis Relative to the General Population"

对“类风湿性关节炎患者髋部骨折发生率及死亡率风险与普通人群的比较”的回应

Abbreviation	Arthritis Care Res
Journal Impact	3.90
Quartiles(Global)	RHEUMATOLOGY(Q1)

ISSN	2151-464X, 2151-4658
h-index	191

Publication Information	Publisher: John Wiley and Sons Inc，Publishing cycle: ，Journal Type: journal，Open Access Journals: No
Basic data	Year of publication: 1996，Proportion of original research papers: 91.69%，Self Citation Rate:5.40%， Gold OA Rate: 22.02%
Average review cycle	网友分享经验：一般,3-6周

Arthritis Care and Research

Journal Citation Format

A journal article with 1 author

A journal article with 2 authors

A journal article with 3 authors

A journal article with 5 or more authors

Books Citation Format

Thesis Citation Format

Web sites Citation Format

Patent Citation Format

Staying up late manually editing references? ivySCI automatically matches journals and helps you generate references with a single click.

Share Submission Experience